| Name | Phenazopyridine hydrochloride |
| Description | Phenazopyridine hydrochloride (Pyridium) is used orally as a urinary tract analgesic. Side effects of phenazopyridine hydrochloride administration can include nausea, interference with the oxygen-carrying capacity of red blood cells (methemoglobinemia), hemolytic anemia as well as renal and hepatic toxicity. It is reasonably anticipated to be a human carcinogen. |
| In vitro | Phenazopyridine directly inhibits the mechanical sensitivity of Aδ-fibers in the bladders of normal rats. |
| In vivo | Phenazopyridine enhances cell viability, strengthens neuronal cell differentiation, synchronizes the state of cell differentiation, and reduces the number of non-neuronal and undifferentiated cells. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (4 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 10 mg/mL (40.05 mM), Sonication is recommended.
|
| Keywords | SodiumChannel | Sodium Channel | Phenazopyridine hydrochloride | Phenazopyridine | Inhibitor | inhibit |
| Inhibitors Related | Rosiglitazone | Phenytoin sodium | Caffeic Acid | Procaine | Lidocaine | Camphor | Probenecid | Valproic Acid | L-Aspartic aicd sodium | 1,4-Cineole | Lidocaine hydrochloride | trans-Cinnamaldehyde |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bitter Compound library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |